Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Update regarding AIM admission of RenalytixAI

November 1, 2018
Download  full announcement Renalytix AI plc, which develops artificial intelligence (“ AI ”) enabled clinical decision support solutions for kidney disease, announces that, further to the announcement by EKF Diagnostics Holdings plc  (“EKF”)  on 31 October confirming that RenalytixAI’s had

RENX Launch of Restricted Offer

October 11, 2018
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY AND RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO

RENX Pricing announcement

October 11, 2018
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION IN RELATION TO THE COMPANY’S QUOTED SECURITIES AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE,

Update regarding proposed IPO of RenalytixAI

August 31, 2018
Further to the Company’s announcement on 4 July 2018 in relation to Renalytix AI plc (“Renalytix AI”), EKF announces that it intends to undertake further market soundings with institutional and other qualifying potential investors, ahead of a prospective equity Fundraising (defined below) by

Exploring funding options for RenalytixAI business

July 4, 2018
The information contained in this announcement is deemed by the company and Renalytix AI Plc to constitute inside information as stipulated under the EU market abuse regulation (596/2014). upon publication of the announcement via a regulatory information service, this information is considered to

Mount Sinai and RenalytixAI exclusive license

May 29, 2018
Mount Sinai Health System (MSHS) and Renalytix AI Plc today have entered into an exclusive multi-year license and collaboration to commercialize artificial intelligence solutions to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk, large-scale
Displaying 131 - 136 of 136